Year in Review: Medlab (ASX:MDC) with Chief Executive Officer, Dr Sean Hall
In this interview by StockHead, Dr Sean Hall, Chief Executive Officer at Medlab takes a look back on the company’s achievements in 2022.
Dr. Sean Hall; Edward Amoroso
Podcast Interview with Medlab Clinical Ltd's (ASX:MDC) Dr Sean Hall with Ari Zoldan on the Ari Zoldan Show. Sean talks thru his views on leadership and the need to innovate ahead of the next 2 big medical needs – mental health and pain.
Jane King interviews Sean Hall, M.D., CEO, Medlab
Jane King interviews Sean Hall, M.D., CEO, Medlab as they discuss new ways to address the biggest health challenges of our time.
Dr Sean Hall interviewed by Ari Zoldan
Podcast Interview with Medlab Clinical Ltd's (ASX:MDC) Dr Sean Hall with Ari Zoldan on the Ari Zoldan Show.
Dr Sean Hall interviewed by Jane King
Jane King interviews Sean Hall, CEO, Medlab. Segment from TV Show 'Innovators with Jane King'. Innovators profile's tech companies and thought leaders in the space. We're showing you a glimpse of the future.
The Future of Medicine Advancement
Sean Hall on The Ari Zoldan Show with Mel Engle & Pamela Bush to discuss the future of medicine advancement
Is this the Future for the COVID-19 Jab ?
Australian researchers work on needle-free COVID vaccinations including nasal spray | 7NEWS
Edison Group – Executive interview with CEO, Dr Sean Hall
In this video, Dr Sean Hall, Medlab’s co-founder and CEO, introduces us to Medlab and its lead programmes and discusses what we can expect from this fast-growing company over the coming months.
Medlab Clinical talks upcoming Phase III NanaBis trial and NanoCelle partnering opportunities
Medlab Clinical Ltd's (ASX:MDC) Dr Sean Hall tells Proactive's Andrew Scott they're focused on achieving regulatory approval for its lead drug candidate NanaBis™.
Small Caps interview of CEO Sean Hall
Small Caps interview of CEO Sean Hall
11-13 LORD ST, BOTANY
BUILDING A, UNIT A5 – A6, BOTANY QUARTER
NSW, 2019, AUSTRALIA
www.medlab.co
OFFICE HOURS: 8:30AM - 5PM EST
AUS: 1300 369 570
AUS: +61 2 8188 0311
USA: +1 947 771 8119
UK: +44 20 8138 0311
FAX: +61 2 9699 3347
Email: [email protected]